

Review Article

Open Access

Beyond Standard Renoprotection: Palm Tocotrienol-Rich Vitamin E and Multi-Hit Residual Renal Risk in Diabetic Kidney Disease-A Translational Review

Loso Judijanto

IPOSS Jakarta

ABSTRACT

Diabetic kidney disease (DKD) remains a major cause of chronic kidney disease, kidney failure, cardiovascular morbidity, and premature mortality despite substantial advances in renoprotective therapy. Sodium-glucose cotransporter-2 inhibitors, renin-angiotensin-system blockade, nonsteroidal mineralocorticoid-receptor antagonists, glucagon-like peptide-1 receptor agonists, and increasingly multidrug cardiorenal strategies have transformed DKD management, yet clinically meaningful residual renal risk persists. Palm-derived tocotrienol-rich vitamin E is of translational interest because it may influence oxidative, inflammatory, endothelial, metabolic, mitochondrial, and potentially fibrotic pathways that remain active during DKD progression. Direct human evidence, however, is preliminary. A Phase IIb randomized trial reported improvements in serum creatinine and estimated glomerular filtration rate, particularly in stage 3 chronic kidney disease, without corresponding improvement in albuminuria, and the apparent filtration benefit disappeared after treatment withdrawal. This qualitative review critically integrates contemporary DKD pathobiology, modern pharmacological renoprotection, tocotrienol pharmacology, randomized human evidence, and the discrepancy between filtration- and albuminuria-based endpoints. A Multi-Hit Residual Renal Risk (MHR3) model is proposed in which evidence-based pharmacotherapy constitutes the therapeutic foundation and tocotrienols are positioned only as an investigational adjunct targeting incompletely controlled biological injury. Future trials should evaluate standardized tocotrienol formulations on optimized contemporary therapy using chronic eGFR slope, repeated albuminuria, cystatin C, tubular biomarkers, mechanistic markers, pharmacokinetic exposure, safety, and adequately long follow-up.

*Corresponding author

Loso Judijanto, IPOSS Jakarta, Indonesia.

Received: September 04, 2026; Accepted: September 08, 2026; Published: September 18, 2026

Keywords: Diabetic Kidney Disease, Tocotrienols, Palm Vitamin E, Tocotrienol-Rich Fraction, Residual Renal Risk, Oxidative Stress, Inflammation, Fibrosis, SglT2 Inhibitors, Adjunctive Renoprotection

JEL Classification: I10; I12; I15; I18; O31

Introduction

Diabetic kidney disease (DKD) is one of the most consequential microvascular complications of diabetes because its clinical importance extends beyond progressive loss of kidney function. DKD markedly increases cardiovascular morbidity, hospitalization, health-care utilization, risk of kidney failure, and premature mortality. Contemporary estimates indicate that chronic kidney disease develops in a substantial proportion of people with diabetes, while diabetes remains a dominant cause of kidney failure worldwide. The burden is particularly challenging because kidney damage often evolves over many years and reflects the cumulative interaction of hyperglycemia, hemodynamic abnormalities, hypertension, metabolic dysfunction, vascular injury, inflammation, oxidative stress, and maladaptive tissue remodeling rather than a single pathological mechanism [1-4].

The therapeutic landscape has changed profoundly during the past several years. Renin-angiotensin-system (RAS) blockade and rigorous control of blood pressure and glycemia remain important components of treatment, but modern management increasingly emphasizes organ protection that is not dependent solely on glucose lowering. Large randomized trials established sodium-glucose cotransporter-2 (SGLT2) inhibitors as major kidney-protective agents across broad CKD populations, while finerenone demonstrated cardiorenal benefits in people with type 2 diabetes and CKD. More recently, semaglutide demonstrated significant kidney-outcome benefits in the FLOW trial, further expanding the therapeutic armamentarium available for patients with DKD [5-11].

The concept of standard care is itself continuing to evolve. Rather than selecting a single “best” renoprotective drug, contemporary practice increasingly seeks complementary pathway coverage. Evidence from trials and pooled analyses supports the biological and clinical logic of combining interventions that influence different components of DKD pathophysiology. In the CONFIDENCE trial, simultaneous treatment with finerenone and empagliflozin reduced urinary albumin-to-creatinine ratio (UACR) more than either intervention alone in patients receiving RAS inhibition, illustrating the potential for additive or complementary biological effects

when mechanistically distinct therapies are combined [10,12-15].

Despite these advances, modern therapy does not abolish renal risk. Patients treated with SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and other protective strategies continue to experience declining estimated glomerular filtration rate (eGFR), progressive albuminuria, cardiovascular events, and kidney failure. The residual risk reflects several factors, including treatment initiated after irreversible structural injury has occurred, heterogeneity of the underlying kidney phenotype, incomplete adherence or tolerability, competing cardiovascular disease, and persistence of biological pathways that are incompletely modified by current pharmacotherapy [10,16-19].

This residual-risk paradigm creates a more clinically relevant framework for evaluating nutritional and bioactive interventions. A compound should no longer be regarded as promising simply because it demonstrates antioxidant or anti-inflammatory activity in an experimental model. Instead, the central question is whether it can produce meaningful incremental biological or clinical benefit after established evidence-based therapy has already been optimized. This distinction is essential in the case of palm-derived tocotrienol-rich vitamin E because tocotrienols possess mechanistically interesting biological properties and have been studied directly in patients with DKD, yet their role within contemporary multidrug renoprotection remains uncertain.

Tocotrienols belong to the vitamin E family but differ structurally from tocopherols through an unsaturated isoprenoid side chain. Palm oil is an important natural source of tocotrienols, and palm-derived tocotrienol-rich fractions commonly contain α -, β -, γ -, and δ -tocotrienol in differing proportions together with tocopherol. Experimental and human evidence suggests that tocotrienols can influence lipid peroxidation, redox signaling, inflammatory processes, lipid metabolism, and selected metabolic outcomes. Nevertheless, systematic reviews reveal considerable heterogeneity in their clinical effects, indicating that formulation, dose, population, disease context, treatment duration, and bioavailability are likely important determinants of response [20-24].

The most important kidney-specific evidence comes from a Phase IIb randomized controlled trial in DKD. Tocotrienol-rich vitamin E treatment was associated with lower serum creatinine and improved creatinine-derived eGFR compared with placebo, with a more pronounced signal among patients with stage 3 CKD. However, the improvement was not accompanied by a significant reduction in UACR, and the measured TGF- β 1 and VEGF-A responses did not provide a straightforward mechanistic explanation. Furthermore, the filtration-associated improvement was no longer evident after washout, raising questions about durability, reversible physiology, treatment dependence, and whether the original observation represented structural nephron preservation [25].

These inconsistencies make DKD particularly suitable for a critical qualitative synthesis. The question is not merely whether tocotrienols “work” but what the available findings might mean in a heterogeneous disease characterized by partially independent glomerular, tubular, vascular, metabolic, inflammatory, and fibrotic processes. Recognition of nonalbuminuric DKD is especially relevant because a substantial subgroup of patients can develop declining filtration without the classical pattern of progressively increasing albuminuria [26-28].

Accordingly, this review evaluates palm tocotrienol-rich vitamin E specifically within a contemporary residual-risk framework. It synthesizes the major biological processes underlying persistent DKD progression, assesses direct and indirect human evidence concerning tocotrienols, analyzes the discordance between creatinine/eGFR and albuminuria, examines the limitations imposed by bioavailability and formulation heterogeneity, and evaluates possible complementarity or redundancy with modern pharmacological therapy. The review then proposes a Multi-Hit Residual Renal Risk (MHR3) model and a next-generation trial strategy designed to determine whether palm tocotrienols can provide clinically meaningful incremental renoprotection.

Literature Review: Conceptual and Theoretical Foundations **DKD is a Heterogeneous Multicomponent Disease**

Historically, DKD was commonly conceptualized as a relatively predictable progression from glomerular hyperfiltration to microalbuminuria, overt proteinuria, declining filtration, and eventually kidney failure. Contemporary evidence has challenged this linear model. Some patients develop albuminuria with relatively preserved filtration, whereas others develop progressive reduction in eGFR with normal or only mildly elevated albumin excretion. Pathological and clinical heterogeneity implies that glomerular, vascular, interstitial, and tubular abnormalities can contribute differently across individuals and disease stages [11,26-28].

The heterogeneous phenotype also has implications for interpretation of clinical trials. Albuminuria remains a powerful risk marker and an important therapeutic target, but it cannot represent all clinically relevant renal biology. Conversely, eGFR integrates filtration across functioning nephrons but does not identify the specific compartment responsible for disease progression. A therapy that preferentially influences renal hemodynamics, tubular energetics, endothelial function, or inflammation might theoretically affect filtration without producing an equivalent albuminuria response. This possibility should not be used to dismiss neutral UACR findings, but it demonstrates why multidimensional assessment is necessary [2,29].

Hemodynamic and Tubular Mechanisms

Hyperglycemia increases filtered glucose and sodium delivery to the proximal tubule, where enhanced reabsorption can reduce sodium chloride delivery to the macula densa and disrupt tubuloglomerular feedback. The resulting afferent arteriolar responses contribute to glomerular hyperfiltration and elevated intraglomerular pressure. These mechanisms are important because SGLT2 inhibition partially restores tubuloglomerular feedback while simultaneously influencing proximal tubular workload and systemic metabolism [30].

The tubular compartment is increasingly regarded as an active driver of DKD rather than merely a downstream victim of glomerular injury. Proximal tubular epithelial cells have high energetic requirements and are therefore particularly vulnerable to metabolic overload, mitochondrial dysfunction, hypoxia, lipid accumulation, oxidative stress, and endoplasmic-reticulum stress. Tubular injury can stimulate cytokine production, recruit inflammatory cells, activate interstitial fibroblasts, and ultimately promote fibrosis, providing a pathway through which metabolic and hemodynamic disturbances become irreversible structural damage [31,32].

Oxidative Stress and Redox Signaling

Oxidative stress is frequently invoked in DKD, but contemporary redox biology is more complex than a simple imbalance between oxidants and antioxidants. Reactive oxygen species serve physiological signaling functions, and pathological effects depend on cellular source, subcellular localization, concentration, duration, and the capacity of endogenous defense systems. Hyperglycemia, mitochondrial dysfunction, NADPH oxidase activation, advanced glycation, inflammation, and lipid peroxidation can all contribute to maladaptive redox signaling [33,34].

The NRF2/KEAP1/ARE pathway is particularly relevant because NRF2 regulates numerous antioxidant and cytoprotective genes. Chronic metabolic disease may impair the capacity of endogenous redox-defense systems to counter persistent oxidative burden. However, recognition of NRF2 biology also illustrates why generic antioxidant supplementation cannot automatically be equated with renal protection. A compound must reach the relevant tissue in adequate concentrations, affect the relevant redox pathway at the relevant disease stage, and ultimately influence clinically meaningful kidney outcomes [33,35].

Inflammation and Inflammasome Activation

Inflammation is another major component of DKD progression. Hyperglycemia, oxidative stress, advanced glycation, lipid abnormalities, and injured renal cells can activate NF- κ B and related transcriptional pathways, increasing cytokine and chemokine production and facilitating leukocyte recruitment. Persistent inflammatory signaling promotes endothelial dysfunction, podocyte injury, tubular damage, and fibrogenesis [2,36].

The NLRP3 inflammasome links metabolic stress with innate immune activation and regulated cell death. Activation promotes maturation of IL-1 β and IL-18 and can facilitate pyroptosis, thereby converting intracellular stress into an inflammatory extracellular signal. Although much of the NLRP3-targeted therapeutic evidence remains preclinical, the pathway demonstrates the intimate interconnection among oxidative stress, inflammatory signaling, cell death, and fibrosis in DKD [37,38].

Advanced glycation and metabolic memory

Advanced glycation end products accumulate during chronic hyperglycemia and may be further influenced by reduced kidney clearance. Binding to receptors such as RAGE can increase oxidative stress, endothelial dysfunction, inflammatory signaling, and extracellular-matrix production. Consequently, glycation provides a mechanistic bridge linking historical glycemic exposure with ongoing vascular and renal injury [39].

Epigenetic mechanisms may contribute to “metabolic memory,” whereby pathological gene-expression patterns persist despite later improvement in glycemic control. DNA methylation, histone modifications, and noncoding RNAs have all been implicated in DKD biology. This persistence provides one explanation for why optimal current metabolic control may not fully reverse disease trajectories established by years of prior metabolic exposure [40].

Endothelial and Microvascular Dysfunction

The glomerular endothelium is exposed continuously to metabolic, hemodynamic, and inflammatory stress. Hyperglycemia, oxidative injury, glycation, impaired nitric-oxide signaling, and altered endothelial-podocyte communication can compromise glomerular homeostasis. Microvascular dysfunction may simultaneously

reduce peritubular oxygen delivery and contribute to tissue hypoxia, amplifying tubular and interstitial damage [41].

Renal hypoxia is especially important because oxygen demand is closely linked to tubular transport. Diabetes can increase transport workload, whereas microvascular disease may reduce oxygen delivery. SGLT2 inhibition appears to modify this energetic imbalance by reducing proximal tubular transport demand, illustrating how therapies initially classified as glucose-lowering agents can influence fundamental renal physiology [30,31].

Mitochondrial Dysfunction

Mitochondria occupy a central position within DKD because renal tubular cells depend heavily on oxidative metabolism. Impaired mitochondrial biogenesis, altered fission and fusion, defective mitophagy, oxidative phosphorylation abnormalities, and excessive mitochondrial ROS generation have all been implicated. A systematic review of human DKD studies reported evidence consistent with mitochondrial dysfunction, strengthening the translational relevance of findings initially identified in experimental systems [42].

Mitochondrial dysfunction may also connect several otherwise separate disease processes. Energetic failure can impair tubular transport and cell survival, excess ROS can activate inflammatory pathways, and disrupted lipid metabolism can promote lipotoxicity and ferroptotic susceptibility. Consequently, therapies that genuinely improve mitochondrial resilience could theoretically affect multiple residual-risk domains simultaneously, although such claims require direct demonstration in patients rather than inference from antioxidant activity alone.

Regulated Cell Death and Fibrosis

DKD progression involves multiple regulated cell-death pathways, including apoptosis, pyroptosis, ferroptosis, and potentially necroptosis. Ferroptosis is particularly relevant to tocotrienol biology because it is characterized by iron-dependent lipid peroxidation and failure of antioxidant defense. Experimental and translational reviews increasingly implicate ferroptosis in diabetic renal injury, although its clinical importance and optimal therapeutic targeting remain under investigation [43-45]. Repeated cell injury eventually promotes maladaptive repair and fibrosis. Tubulointerstitial fibrosis is not simply an accumulation of extracellular matrix but a dynamic process involving fibroblast activation, immune cells, epithelial stress, endothelial dysfunction, hypoxia, metabolic reprogramming, and altered cell-cell signaling. Recent work emphasizes that metabolism, inflammation, and fibrosis are tightly interconnected, making fibrosis the downstream product of multiple upstream “hits” rather than an isolated pathway [46].

Contemporary Pharmacological Renoprotection

The clinical importance of SGLT2 inhibition has been established across multiple kidney-outcome trials. DAPA-CKD demonstrated substantial reduction in kidney and cardiovascular events with dapagliflozin in patients with CKD, while benefits were also evident in advanced CKD subgroups. EMPA-KIDNEY expanded the evidence to a broader CKD population, and subsequent follow-up demonstrated that some cardiorenal benefit persisted after discontinuation of blinded study treatment. Collaborative meta-analysis further supports a robust kidney-protective effect of SGLT2 inhibitors across diabetes and CKD populations [5,8,47-49].

Finerenone provides a complementary pathway through selective nonsteroidal mineralocorticoid-receptor antagonism. FIDELIO-DKD demonstrated reduction of kidney outcomes in type 2 diabetes with CKD, while FIGARO-DKD demonstrated cardiovascular benefit in a broader CKD spectrum. The pooled FIDELITY analysis reinforced the combined kidney and cardiovascular evidence, although hyperkalemia remains an important treatment consideration requiring surveillance [6,7,12,50].

GLP-1 receptor agonists have now moved from primarily metabolic and cardiovascular therapy into explicit kidney-risk reduction. In FLOW, semaglutide reduced clinically important kidney outcomes and slowed eGFR decline among people with type 2 diabetes and CKD. Meta-analyses published subsequently support kidney and cardiovascular benefits of GLP-1 receptor agonism in CKD populations, although background-treatment patterns and specific trial populations remain important when generalizing findings [9,51,52].

Increasing evidence favors complementary combination therapy. ROTATE-3 demonstrated greater albuminuria reduction with combined dapagliflozin and eplerenone than either intervention alone, while CONFIDENCE demonstrated greater UACR reduction with finerenone plus empagliflozin than with either agent separately. These findings are central to the present review because they raise the evidentiary standard for any proposed adjunctive intervention: a candidate must demonstrate benefit within an increasingly comprehensive pharmacological environment rather than against historical standards of care [14,15,53].

Tocotrienol biology and translational pharmacology

Tocotrienols and tocopherols share the chromanol ring characteristic of vitamin E but differ in the saturation of their side chains. Tocotrienols contain an unsaturated isoprenoid tail, which can influence membrane distribution and biological behavior. Palm tocotrienol-rich fractions usually contain several tocotrienol isomers together with variable tocopherol content, meaning that “tocotrienol supplementation” is not a pharmacologically uniform intervention [20,24].

Systematic evidence suggests potential effects on inflammation, oxidative stress, lipid metabolism, and glycemic parameters, but findings are inconsistent. A meta-analysis by Khor et al. did not demonstrate universal improvement across inflammatory and oxidative biomarkers. Zuo et al. reported heterogeneous lipid effects, while Phang et al. identified modest improvement in HbA1c in people with type 2 diabetes without uniform improvements in other cardiometabolic measures. These findings support biological activity but argue against presenting tocotrienols as universally effective antioxidants or anti-inflammatory agents [21,22,23].

Pharmacokinetics represent another major translational limitation. Absorption and systemic exposure vary with formulation, food intake, source, and isomer. Sharif et al [54]. highlighted substantial variability in human tocotrienol pharmacokinetics and bioavailability. Consequently, a nominal dose such as 400 mg/day does not by itself establish equivalent tissue exposure across products. Future renal studies should measure circulating tocotrienol isomers and relate biological and kidney responses to achieved exposure.

Method

This study used a qualitative, critical, translational literature-review design, not a systematic literature review or meta-

analysis. The objective was to integrate clinical, mechanistic, pharmacological, and therapeutic evidence around a specific translational question: whether palm tocotrienol-rich vitamin E warrants further investigation as an adjunct targeting residual renal risk in DKD after contemporary evidence-based therapy has been optimized.

The literature framework prioritized publications from 2020 through 2026. Evidence domains included contemporary DKD pathophysiology, residual-risk concepts, kidney-outcome trials of modern pharmacotherapy, randomized tocotrienol studies, systematic reviews and meta-analyses of tocotrienol supplementation, human pharmacokinetic evidence, DKD phenotype research, biomarker studies, and mechanistic reviews addressing oxidative stress, inflammation, advanced glycation, mitochondrial dysfunction, tubular injury, regulated cell death, and fibrosis. PubMed/MEDLINE, Scopus-indexed journal literature, Web of Science-indexed literature, and major publisher databases were treated as principal information sources.

Evidence was prioritized according to the question being addressed rather than through a single universal hierarchy. Claims regarding clinical renoprotection relied preferentially on large randomized kidney-outcome trials, major pooled analyses, and contemporary guidelines or consensus reports. These included DAPA-CKD, FIDELIO-DKD, FIGARO-DKD, EMPA-KIDNEY, FLOW, FIDELITY, and CONFIDENCE, together with contemporary ADA and KDIGO recommendations [4-7,9,14,17,18].

Claims regarding tocotrienol effects were anchored primarily to randomized human evidence and quantitative syntheses rather than experimental studies. The DKD Phase IIb study was therefore weighted more strongly than generic antioxidant evidence, while systematic reviews by Khor et al., Phang et al., Rahayu et al., and Looi et al. were used to evaluate consistency across populations and outcomes. The 2025 randomized CKD study by Trugilho et al. was additionally considered because it provides more recent information regarding lipid and inflammatory responses in dialysis and nondialysis CKD.

Thematic coding organized the literature into seven domains: contemporary renoprotection; residual biological risk; tocotrienol pharmacology; direct renal evidence; endpoint discordance; potential interactions with standard therapy; and requirements for future trials. Mechanistic information was subsequently synthesized into six residual pathogenic “hits”: oxidative/redox dysregulation, inflammation, advanced glycation/metabolic memory, endothelial/microvascular dysfunction, mitochondrial-metabolic-tubular injury, and regulated cell death/fibrosis.

The analysis deliberately emphasized discordant and negative evidence. Neutral UACR findings, lack of consistent inflammatory biomarker improvement, washout behavior, small sample size, formulation heterogeneity, surrogate endpoints, and absence of trials under fully optimized contemporary background therapy were treated as central evidence rather than limitations to be minimized. This critical approach was intended to distinguish mechanistic plausibility from demonstrated clinical efficacy.

Results

Thematic Synthesis

Theme 1: Modern Therapy has Substantially Reduced, but Not Eliminated, DKD Progression

The first major theme is that the therapeutic context has changed

sufficiently that older adjunctive-treatment evidence must be reinterpreted. SGLT2 inhibitors now provide robust kidney protection across CKD populations. Dapagliflozin reduced major kidney and cardiovascular outcomes in DAPA-CKD, including benefit among patients with advanced CKD, while empagliflozin demonstrated kidney protection in EMPA-KIDNEY. Sotagliflozin likewise provided evidence that sodium–glucose transport inhibition can influence major cardiovascular outcomes in people with diabetes and CKD [5,8,47,55].

The second pharmacological advance is mineralocorticoid-receptor antagonism. Finerenone reduces detrimental mineralocorticoid-receptor activation without the steroidal structure of older MRAs. FIDELIO-DKD and FIGARO-DKD established kidney and cardiovascular benefits, and FIDELITY confirmed clinically relevant effects across the combined trial population. Safety remains important because hyperkalemia occurs more often with finerenone than placebo, although careful selection and monitoring can mitigate this risk [6,7,12,50].

A third major advance is the emergence of GLP-1 receptor agonists as kidney-outcome therapies. FLOW showed that semaglutide reduced major kidney events in patients with type 2 diabetes and CKD, adding renal protection to previously established metabolic and cardiovascular benefits. Subsequent quantitative syntheses support a broader kidney-protective signal for this therapeutic class [9,51,52].

Most importantly, therapeutic development is moving toward layered combination therapy. Greater UACR reduction with finerenone plus empagliflozin in CONFIDENCE demonstrates that overlapping but mechanistically distinct interventions can yield additional biological benefit. Current standards consequently frame DKD management as comprehensive cardiorenal risk reduction rather than sequential glucose lowering alone [4,14].

Residual risk nonetheless persists. Even successful kidney-outcome trials record substantial numbers of progressive kidney events among actively treated participants. This residual burden is the appropriate biological space within which tocotrienols must now be evaluated. The relevant comparator is not placebo without modern treatment but optimized therapy that already modifies hemodynamics, tubular physiology, hormonal signaling, cardiovascular risk, metabolic stress, and aspects of inflammation and fibrosis [16,18].

The evolution of therapy and the consequent narrowing of the untreated biological space are illustrated conceptually in Figure 1. This framing emphasizes that increasingly comprehensive evidence-based pharmacotherapy reduces, but does not eliminate, the residual-risk domain in which a credible adjunctive intervention would need to demonstrate incremental benefit.




Figure 1: Evolution of Diabetic Kidney Disease Therapy and the Residual-Risk Space Available for Adjunctive Interventions

Figure 1 emphasizes that the evidence supporting tocotrienols and modern pharmacological agents is not equivalent. The established drugs occupy the therapeutic foundation because their benefits have been demonstrated in large outcome trials, whereas tocotrienols remain outside that foundation until incremental efficacy can be demonstrated.

Theme 2: Residual DKD is a Multi-Hit Biological Network

The second theme is that residual DKD cannot be adequately described as persistent oxidative stress alone. Contemporary molecular studies portray DKD as a network involving glomerular hemodynamic stress, podocyte loss, tubular metabolic overload, mitochondrial dysfunction, endothelial injury, hypoxia, advanced glycation, immune activation, lipid abnormalities, dysregulated cell death, and fibrosis. [1,3,56].

Oxidative/redox dysregulation forms one node of this network. Hyperglycemia, damaged mitochondria, inflammatory signaling, AGEs, and lipid peroxidation create overlapping sources of ROS. Persistent ROS can activate inflammatory and profibrotic signaling, but the pathological importance depends on subcellular context and endogenous defense pathways, meaning that simply increasing antioxidant intake may not necessarily correct the relevant redox disturbance [33,34].

Inflammation constitutes a second hit. Activation of NF- κ B and NLRP3-related pathways increases cytokine production and promotes inflammatory cell recruitment, while pyroptosis can amplify inflammation through regulated membrane disruption and cytokine release. In parallel, AGE-RAGE signaling adds persistent metabolic and inflammatory stimulation, potentially reinforced by epigenetic metabolic memory [37-40].

Endothelial dysfunction and microvascular damage form a third interconnected component. Impaired nitric-oxide signaling, oxidative stress, inflammation, capillary rarefaction, and altered glomerular endothelial behavior can disturb both glomerular filtration and tissue oxygenation. These processes intersect directly with tubular hypoxia and mitochondrial stress [31,41].

Mitochondrial-metabolic-tubular stress constitutes another major residual domain. Tubular cells must sustain high ATP production to support transport, making them vulnerable to mitochondrial dysfunction. Human evidence of altered mitochondrial biology in DKD reinforces the importance of this pathway. Repeated metabolic and oxidative injury then increases susceptibility to regulated cell-death mechanisms, including ferroptosis and pyroptosis [41-43].

Finally, these insults converge on fibrosis. Fibrotic remodeling incorporates metabolic changes, immune activation, fibroblast expansion, capillary loss, extracellular-matrix deposition, and failed tissue repair. Once substantial fibrosis is established, the proportion of kidney dysfunction that remains biologically reversible may decrease markedly [45,46].

Theme 3: Tocotrienols Plausibly Intersect Several Residual Pathways, But Mechanistic Breadth is Not Clinical Proof

Palm tocotrienol-rich vitamin E is scientifically interesting because it is not expected to operate through a single renal transporter or receptor. Tocotrienols may influence membrane lipid oxidation, antioxidant defenses, inflammatory signaling, metabolic variables, and potentially endothelial function. This multidimensional profile fits the biological complexity of residual DKD and differentiates tocotrienols conceptually from a single-target drug.

However, broad mechanistic plausibility creates its own interpretive danger. When a compound can theoretically influence many pathways, almost any favorable outcome can be retrospectively attributed to one of them. The higher-quality human tocotrienol literature therefore becomes critical. Khor et

al. found that tocotrienol supplementation did not consistently improve all measured inflammatory and oxidative-stress markers. Zuo et al. identified heterogeneous lipid responses. Phang et al. reported modest improvement in glycemic control but not uniform improvement in cardiometabolic or inflammatory measures. Thus, tocotrienol biology in humans is context-dependent rather than universally favorable.

The systematic review by Looi et al, which evaluated 30 randomized trials involving more than 2,600 participants, similarly demonstrated that the clinical literature spans diverse populations, formulations, doses, and outcomes. The findings support continued research but also reinforce the need for standardization. Furthermore, antioxidant trials in diabetic nephropathy more broadly have produced mixed results, indicating that oxidative plausibility alone is insufficient for establishing renal disease modification.

Theme 4: Direct Human DKD Evidence Provides a Signal, but not Definitive Proof

The strongest argument for continued tocotrienol research is the existence of direct randomized human DKD evidence. In the Phase IIb trial by Koay et al., tocotrienol-rich vitamin E produced favorable changes in serum creatinine and creatinine-derived eGFR over the intervention period. The signal was particularly notable among participants with stage 3 CKD, raising the hypothesis that clinically established renal impairment may represent a phenotype in which tocotrienol effects become more detectable [25].

Nevertheless, several aspects prevent the study from establishing disease modification. The sample size was relatively small compared with contemporary kidney-outcome trials. UACR did not improve significantly, meaning that the filtration-associated effect was not accompanied by a corresponding reduction in a major glomerular injury marker. TGF- β 1 and VEGF-A measurements likewise did not produce a coherent biomarker explanation for the renal-function signal [25].

The washout finding is equally important. After discontinuation, the favorable creatinine/eGFR difference was no longer evident. This observation can support an exposure-dependent biological effect, but it also argues against assuming permanent structural recovery. Effective chronic therapies often lose benefit when discontinued, so reversibility does not disprove pharmacological activity. However, it requires investigators to distinguish continuous physiological modulation from durable preservation of nephron structure.

A 2025 randomized study provides additional evidence that tocotrienol effects in CKD may depend on clinical context. Trugilho et al [57]. observed differential changes in cardiovascular risk markers among dialysis and nondialysis patients, including lipid-related effects in hemodialysis participants and CRP-related effects in nondialysis CKD. Yet molecular inflammatory markers were not uniformly altered. These findings reinforce the possibility that disease stage, renal replacement status, baseline inflammation, and metabolic characteristics modify responsiveness.

To make the limited human evidence base transparent, Table 1 summarizes the principal clinical and synthesis studies that directly inform the tocotrienol-DKD hypothesis. The comparison highlights the contrast between the renal filtration signal in DKD, short-term inflammatory or lipid effects in CKD, and the heterogeneity of findings across broader randomized evidence.

Table 1. Human Evidence Most Directly Relevant to Palm Tocotrienol-Rich Vitamin E in DKD and CKD

Study	Population and design	Exposure / duration	Key findings	Principal translational limitation
Koay et al. ²⁵	59 adults with DKD; randomized, double-blind, placebo-controlled Phase IIb trial; stage 3 subgroup n=37	Tocotrienol-rich vitamin E 400 mg/day; 12 months plus 6-month washout	Lower serum creatinine and higher creatinine-derived eGFR; no significant UACR improvement; no clear TGF-β1 or VEGF-A change; filtration signal not maintained after washout	Modest sample; surrogate renal endpoints; subgroup uncertainty; trial predates current multidrug renoprotection
Trugilho et al. ⁵⁷	33 CKD completers: 17 hemodialysis and 16 nondialysis participants; double-blind randomized placebo-controlled trial	Tocotrienol-rich fraction 300 mg/day; 3 months	Lower LDL and total cholesterol in hemodialysis participants and lower CRP in nondialysis CKD; NRF2 and NF-κB expression unchanged	Small heterogeneous CKD groups; not DKD-specific; short duration; no kidney-function outcome
Khor et al. ²²	Systematic review and meta-analysis of randomized controlled trials	Tocotrienol supplementation; heterogeneous formulations and durations	No uniform improvement across inflammatory and oxidative-stress biomarkers, although selected subgroup signals were reported	Substantial heterogeneity in populations, formulations, doses, and biomarkers; indirect for renal outcomes
Phang et al. ²³	Systematic review and meta-analysis of randomized trials in type 2 diabetes	Tocotrienol-rich fraction / tocotrienols; heterogeneous regimens	Modest HbA1c improvement but no uniform improvement across blood-pressure or inflammatory outcomes	Metabolic rather than kidney-outcome evidence; heterogeneous exposure and background treatment
Looi et al. ²⁴	Systematic review of 30 randomized trials involving >2,600 participants	Palm tocotrienol-rich fraction; heterogeneous doses and durations	Clinical effects varied by population, formulation, dose, duration, and outcome domain	Broad health-evidence synthesis with limited kidney-specific efficacy data

Table 1 shows that direct kidney-specific evidence remains much narrower than the broader tocotrienol literature. The strongest renal signal derives from one modest-sized DKD trial, whereas the remaining evidence mainly supports context-dependent biomarker or metabolic effects rather than durable preservation of kidney function.

Theme 5: eGFR–UACR Discordance is Scientifically Informative

The discrepancy between improved creatinine/eGFR and unchanged albuminuria should be one of the defining analytical features of this review. It should neither be dismissed as evidence that the study “failed” nor minimized to protect a positive narrative. Instead, it provides an opportunity to ask which renal compartments or physiological processes may have been affected.

UACR largely reflects glomerular albumin permeability together with tubular albumin handling. Creatinine-derived eGFR, in contrast, estimates filtration function and is influenced by functioning nephron mass as well as non-GFR determinants of serum creatinine. These measurements therefore interrogate different but overlapping renal domains [29,58].

Recognition of nonalbuminuric DKD strengthens this interpretation. Meta-analytic evidence indicates that patients with reduced kidney function but little albuminuria constitute a distinct and increasingly recognized phenotype, with comparatively greater vascular or tubulointerstitial involvement and less classical glomerular pathology in some cohorts. Reviews similarly emphasize that eGFR decline can occur without the expected preceding rise in albuminuria [26–28].

Consequently, an intervention could theoretically improve tubular energetics, microvascular physiology, endothelial function, or another determinant of filtration without producing a large UACR change. Conversely, serum creatinine can change because of muscle mass, dietary intake, creatinine generation, tubular secretion, hydration, and other non-GFR factors. Therefore, future studies must reproduce any renal signal using filtration measures less dependent on creatinine alone.

The biological basis of endpoint discordance is summarized in Figure 2, which separates glomerular albumin-permeability processes from vascular–tubular–metabolic determinants of filtration while retaining their biological overlap. This distinction is central to interpreting the Phase IIb trial because a filtration signal occurred without a parallel albuminuria response.




Figure 2: Why Serum Creatinine/eGFR and UACR May Respond Differently to an Intervention in Diabetic Kidney Disease

The figure is intended to prevent binary interpretation of the Phase IIb findings. A future trial should measure repeated UACR, creatinine, cystatin C, and chronic eGFR slope concurrently, with tubular and mechanistic biomarkers used to determine which renal compartment is most responsive.

Theme 6: Bioavailability is a Major but Underappreciated Determinant

Clinical tocotrienol studies cannot be interpreted solely on the basis of nominal dose. Tocotrienols are lipophilic compounds whose absorption depends on digestive conditions, food intake, formulation, and delivery system. Different isomers also display different pharmacokinetic profiles. Sharif et al. demonstrated substantial variability in tocotrienol bioavailability across human studies [54].

This variability has direct consequences for DKD research. If biological effects require threshold tissue exposure, two formulations given at an identical labelled dose may generate different renal responses. CKD may further alter gastrointestinal physiology, protein binding, metabolism, nutritional status, and concomitant medication use. Future trials should therefore quantify plasma α -, γ -, and δ -tocotrienol concentrations and analyze exposure–response relationships.

The formulation issue also affects reproducibility. A trial result obtained with one specific palm tocotrienol-rich preparation should not automatically be generalized to all vitamin-E supplements or even to all tocotrienol formulations. Standardization of isomer composition, tocopherol content, excipients, manufacturing

quality, administration with food, and storage stability is necessary before multicenter efficacy testing [20,24,54].

Theme 7: Existing trials Do Not Answer the Contemporary Incremental-Benefit Question

The central translational limitation is that the clinical tocotrienol evidence was generated before the present multidrug DKD era was fully established. A contemporary patient eligible for tocotrienol research may already be receiving an ACE inhibitor or ARB, an SGLT2 inhibitor, finerenone, a GLP-1 receptor agonist, a statin, individualized antihypertensive therapy, and improved glycemic management. Several of these therapies affect pathways that might otherwise be proposed as targets of tocotrienols [4,17,18].

Two competing hypotheses therefore emerge. Under the redundancy hypothesis, contemporary drugs already suppress enough oxidative, inflammatory, endothelial, metabolic, and fibrotic injury that tocotrienols would add little meaningful benefit. Under the complementarity hypothesis, tocotrienols modify residual lipid peroxidation, membrane, redox, inflammatory, or mitochondrial processes that remain insufficiently addressed by standard drugs. Existing data cannot distinguish these hypotheses.

The evidentiary distance between biological plausibility and definitive renal protection is illustrated in Figure 3. The ladder distinguishes evidence that is already available from the major uncertainty created by neutral UACR and washout findings and from the higher-level clinical evidence that remains necessary.




Figure 3: Translational Evidence Ladder for Palm Tocotrienol-Rich Vitamin E in Diabetic Kidney Disease

The ladder deliberately separates plausibility, biomarker effects, surrogate outcomes, and hard clinical outcomes. The objective is to ensure that each level of evidence is interpreted according to its own strength rather than allowing mechanistic findings to substitute for clinical outcome data. This structure also makes clear that the existing randomized filtration signal remains several evidentiary steps below definitive proof of long-term renoprotection.

Discussion and Analysis

The Multi-Hit Residual Renal Risk Model

The evidence synthesized in this review supports a conceptual model in which residual DKD arises from several interacting pathogenic domains that remain active to varying degrees despite contemporary therapy. The proposed Multi-Hit Residual Renal

Risk (MHR3) model contains four hierarchical layers.

The first layer is the evidence-based therapeutic foundation. It includes individualized glycemic management, blood-pressure control, RAS blockade when indicated, SGLT2 inhibition, finerenone where appropriate, GLP-1 receptor agonism where appropriate, lipid management, smoking cessation, weight management, and comprehensive cardiovascular-risk reduction. This foundation is not optional in the model because withholding therapies with proven kidney-outcome benefits merely to create a larger treatment signal for a supplement would answer a clinically obsolete question.

The second layer contains six residual pathogenic hits. These are oxidative/redox dysregulation; inflammatory and inflammasome activity; glycation and metabolic memory; endothelial and microvascular dysfunction; mitochondrial–metabolic–tubular stress; and regulated cell death/fibrosis. These domains are intentionally overlapping. Oxidative stress promotes inflammation; mitochondrial dysfunction generates ROS; lipid peroxidation can facilitate ferroptosis; inflammation promotes fibrosis; and vascular injury amplifies tissue hypoxia [34,37,42,43,46].

The third layer consists of investigational adjunctive tocotrienol exposure. Tocotrienols are positioned across selected residual hits rather than as a new therapeutic foundation. Their strongest conceptual relevance lies in lipid-peroxidation and redox biology, with possible additional relevance to inflammatory, metabolic, and endothelial pathways. Effects on advanced fibrosis or structural nephron preservation should be presented more cautiously because direct human evidence remains inadequate.

The fourth layer is the outcome hierarchy. Molecular biomarkers occupy the lowest evidentiary level, followed by cellular or organ-specific biomarkers, albuminuria and filtration surrogates, chronic eGFR slope, sustained major eGFR decline, kidney failure, cardiovascular outcomes, and mortality. An adjunctive intervention becomes progressively more clinically credible as evidence moves upward through this hierarchy.

The complete framework is presented in Figure 4, which represents the primary conceptual contribution of this review. It visually separates optimized evidence-based therapy, persistent biological injury, the investigational tocotrienol layer, and an outcome hierarchy that progresses from biomarkers to hard kidney and cardiovascular events.




Figure 4: Multi-Hit Residual Renal Risk (MHR3) Model for Positioning Palm Tocotrienol-Rich Vitamin E in Contemporary DKD.

The model makes two explicit claims. First, residual biological injury exists even when standard care is optimized. Second, the existence of residual injury does not prove that tocotrienols can modify it. The MHR3 model is therefore a framework for generating falsifiable hypotheses rather than a diagram of established efficacy.

Reinterpreting the Filtration Signal

Four broad explanations may account for the creatinine/eGFR findings of the Phase IIb trial. The first is a true renal-function hypothesis, under which tocotrienol exposure improves a biological process sufficiently to preserve or increase filtration. Candidate mechanisms include endothelial function, oxidative balance, renal microcirculation, mitochondrial efficiency, or tubular metabolism. The second is a functional or hemodynamic hypothesis. Kidney filtration can change without corresponding structural nephron regeneration. Modern SGLT2 trials themselves demonstrate how acute and chronic eGFR behavior can differ, although the mechanisms would not necessarily be the same for tocotrienols. If tocotrienols alter renal perfusion, vascular tone, or metabolic demand, a reversible filtration effect could occur without major changes in albumin permeability.

The third is a creatinine-determinant hypothesis. Creatinine is influenced by factors independent of GFR, including muscle mass, diet, tubular secretion, and systemic metabolic conditions. An intervention-related change in creatinine generation or handling could therefore change creatinine-derived eGFR without an equivalent change in true GFR.

The fourth is a statistical-variability hypothesis. Small trials are vulnerable to regression to the mean, baseline imbalance, random variation, and unstable subgroup effects. The stage 3 CKD observation is biologically plausible but requires replication in a prespecified, adequately powered subgroup before it can be accepted as a treatment-effect modifier.

Future trials can distinguish these possibilities by combining serum creatinine with cystatin C and, ideally, measured GFR in a mechanistic subset. Concordance between creatinine- and cystatin-C-based estimates would strengthen the argument for a genuine filtration effect. A persistent difference in chronic eGFR slope over 18–24 months would be substantially more persuasive than isolated changes at individual visits.

The Significance of Neutral Albuminuria

The neutral UACR result should remain visible throughout interpretation rather than being relegated to a limitation. Albuminuria is a powerful marker of DKD progression and therapeutic response, and many established kidney-protective agents reduce albuminuria. Failure to improve UACR therefore represents meaningful negative evidence.

However, nonalbuminuric DKD demonstrates that declining filtration and glomerular albumin leakage are not obligatorily coupled. Patients with nonalbuminuric DKD may show comparatively greater vascular, ischemic, or tubulointerstitial changes, while retaining less severe classical glomerular lesions [26]. This phenotype creates a plausible setting in which a filtration-related effect could occur without major UACR change.

A future trial should consequently stratify participants by albuminuric phenotype. Patients with substantial albuminuria may provide greater sensitivity for detecting glomerular-barrier effects, whereas nonalbuminuric or moderately albuminuric stage 3 CKD may be particularly useful for testing tubular, vascular, or metabolic hypotheses. Repeated first-morning UACR measurements should be used to minimize biological variability.

Potential Interaction with SGLT2 Inhibitors

SGLT2 inhibitors alter proximal sodium and glucose handling, restore aspects of tubuloglomerular feedback, reduce intraglomerular pressure, influence tubular energetic demand, and produce systemic metabolic and cardiovascular effects. Several downstream effects—including reduced hypoxic stress, altered inflammatory signaling, and improved cellular energetics—could overlap with mechanisms proposed for tocotrienols [30].

Overlap creates both opportunity and risk. If tocotrienols affect a distinct proximal mechanism—such as membrane lipid peroxidation—additional benefit may remain possible even when SGLT2-mediated tubular physiology has been optimized. Conversely, if most clinically relevant tocotrienol effects are merely secondary reductions in oxidative stress that are already achieved through SGLT2-mediated metabolic improvements, the incremental benefit could be minimal.

Future trials should therefore require stable SGLT2 inhibitor therapy whenever clinically indicated rather than exclude it. Prespecified interaction analyses and biomarker measurements should determine whether tocotrienols produce additional redox, inflammatory, or tubular changes beyond those achieved by SGLT2 therapy.

Potential Interaction with Finerenone

Finerenone acts through mineralocorticoid-receptor antagonism and has demonstrated kidney and cardiovascular benefits. Mineralocorticoid-receptor signaling influences inflammation, fibrosis, oxidative biology, vascular function, and sodium handling. Tocotrienol mechanisms may therefore overlap with some downstream pathways modified by finerenone [6,12].

CONFIDENCE is particularly relevant because it demonstrates that pathway overlap does not necessarily eliminate additivity. Finerenone and empagliflozin produced greater UACR reduction together than individually. However, the lesson should not be generalized automatically to tocotrienols. CONFIDENCE provides a model for how complementarity can be tested, not evidence that all multi-pathway combinations will be beneficial [14].

Finerenone use should therefore be optimized before randomization in future tocotrienol trials whenever clinically indicated. Hyperkalemia monitoring remains important because CKD participants are medically complex, even if tocotrienols themselves are not expected to directly reproduce finerenone's potassium-related pharmacology [50].

Potential interaction with GLP-1 receptor agonists

GLP-1 receptor agonists influence glycemia, body weight, cardiovascular risk, and systemic metabolism, and FLOW demonstrated direct kidney-outcome benefit for semaglutide in type 2 diabetes with CKD [9]. Their systemic effects may also reduce inflammatory or oxidative burden indirectly.

This again narrows the potential residual biological space available to tocotrienols. A clinically relevant tocotrienol study should therefore include participants receiving GLP-1-based therapy when indicated and should regard GLP-1 use as an important stratification variable. If tocotrienols retain measurable redox or renal effects in participants receiving SGLT2 inhibition, finerenone, and GLP-1 receptor agonism, the evidence for genuine complementary biology would become considerably stronger.

Disease Stage May Modify Response

The stronger filtration signal reported among participants with stage 3 CKD raises a clinically important hypothesis. Moderate CKD may represent a window in which residual oxidative and inflammatory burden is sufficiently high for biological effects to be detectable but structural damage has not yet progressed to extensive irreversible fibrosis.

This hypothesis must remain provisional. More advanced disease can increase oxidative burden but simultaneously reduce reversible nephron reserve. Conversely, earlier disease may offer greater capacity for long-term prevention even if short-term biochemical effects are smaller. A definitive study should therefore prespecify CKD-stage strata and formally test treatment interaction.

Stage 3 CKD is nevertheless a reasonable initial enrichment population because it combines measurable progression risk, adequate event rates, and sufficient remaining kidney function for serial biomarker analysis. An eGFR range of approximately 30–60 mL/min/1.73 m² could provide a practical population for a next Phase II trial, with appropriate exclusion criteria and safety monitoring.

The Importance of Treatment Durability

The loss of the original renal-function signal after tocotrienol washout should be used constructively in future study design. Rather than viewing washout only as evidence against benefit, investigators should characterize the temporal relationship among exposure, biological markers, and filtration.

If tocotrienol concentrations fall after discontinuation and redox or inflammatory markers worsen in parallel with eGFR, this would support a biologically coherent exposure-dependent effect. If creatinine changes reverse while cystatin C and mechanistic biomarkers remain unchanged, the possibility of a creatinine-specific or non-GFR effect would become more plausible.

A planned post-treatment follow-up period should therefore be incorporated into future trials. The objective is not to require permanent benefit after therapy is stopped; many effective chronic treatments require continued administration. Instead, washout can function as a mechanistic experiment clarifying whether observed effects track with drug exposure.

Pharmacokinetic Standardization Must Precede Definitive Efficacy Testing

The future development pathway should treat tocotrienols more like a pharmacologically characterized intervention and less like a generic dietary supplement. Investigators should specify the precise α -, β -, γ -, and δ -tocotrienol composition, tocopherol content, excipients, manufacturing specifications, storage conditions, and dosing instructions.

Participants should receive standardized guidance regarding administration with food because fat-dependent absorption can influence exposure. Plasma tocotrienol concentrations should be measured at baseline and at predefined treatment intervals. Exposure–response modeling should test whether changes in eGFR, cystatin C, UACR, inflammatory biomarkers, or oxidative markers correlate with achieved tocotrienol concentrations [54].

Such pharmacokinetic confirmation would also help distinguish biological failure from inadequate delivery. A negative trial in which participants failed to achieve sufficient tocotrienol exposure should not be interpreted in the same manner as a negative trial demonstrating high, sustained exposure without corresponding biological or renal effects.

A Next-Generation Randomized Trial

A future study should enroll adults with type 2 diabetes and CKD who remain at meaningful risk of progression despite stable contemporary therapy. Stage 3 CKD is a logical enrichment population because of the signal observed previously, but recruitment should include prespecified albuminuric and nonalbuminuric strata.

Before randomization, participants should undergo a run-in period to optimize evidence-based therapy. ACE inhibitor or ARB treatment should be stable when indicated, SGLT2 inhibition should be used when tolerated and appropriate, finerenone should be considered according to albuminuria, potassium, and eGFR criteria, and GLP-1 receptor agonists should be incorporated where clinically indicated. Blood pressure, glycemia, lipid management, smoking, and adherence should also be optimized in accordance with contemporary standards [4,17,18].

Participants could then be randomized to a chemically standardized palm tocotrienol-rich vitamin E formulation or placebo. The dose should be informed by prior renal trials, but equivalence should be based on formulation and pharmacokinetic exposure rather than milligram dose alone. A pharmacokinetic lead-in could be considered if a new formulation is used.

The primary endpoint for a sufficiently powered Phase II study should preferably be chronic eGFR slope rather than a single creatinine measurement. Repeated creatinine and cystatin C should be incorporated, with measured GFR in a mechanistic subset if feasible. Repeated first-morning UACR should be a major secondary endpoint.

Tubular biomarkers should be included because the endpoint discordance hypothesis specifically implicates non-glomerular mechanisms. Kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and other validated tubular markers may provide useful information. Emerging metabolomic biomarkers could additionally characterize changes in glucose, lipid, amino-acid, and mitochondrial metabolism, although exploratory omics must remain separate from confirmatory renal endpoints [59].

Mechanistic biomarkers should be parsimonious and hypothesis-driven. Oxidative markers could include validated lipid-peroxidation products rather than nonspecific total antioxidant measures. Inflammatory assessment might include hs-CRP and a limited cytokine panel. Glycation, endothelial, and fibrosis markers should be selected only where assay validity and biological rationale are strong.

Treatment duration should be at least 18–24 months if chronic eGFR slope is a major endpoint. Shorter studies may identify pharmacodynamic effects but are unlikely to establish convincing disease modification. A subsequent Phase III outcome trial would require substantially larger enrollment and a composite such as sustained major eGFR decline, kidney failure, or renal/cardiovascular death.

The proposed clinical-development strategy is summarized in Figure 5. The figure translates the MHR3 framework into a testable trial pathway in which phenotyping, optimized background therapy, pharmacokinetic confirmation, mechanistic assessment, and clinically meaningful kidney outcomes are evaluated together.




Figure 5: Blueprint for a Contemporary Randomized Trial of Adjunctive Palm Tocotrienol-Rich Vitamin E in Diabetic Kidney Disease

This design deliberately asks a more difficult but clinically meaningful question than earlier tocotrienol studies: whether a standardized preparation provides measurable renal benefit when current evidence-based therapy has already minimized as much modifiable risk as reasonably possible. Its central design principle is that any tocotrienol effect must be incremental to optimized standard care rather than a substitute for it.

Precision Phenotyping and Responder Identification

An average treatment effect may conceal clinically relevant heterogeneity. If tocotrienol benefit depends on residual oxidative or inflammatory burden, participants with elevated baseline markers might respond differently from those with advanced fibrosis and relatively little reversible metabolic injury.

A future trial could therefore prespecify biomarker-defined subgroup analyses. However, this approach should avoid post hoc “responder” narratives. Biomarker thresholds must be defined prospectively, statistical interaction tests should be adequately powered, and any responder phenotype should be validated independently [19,60].

Albuminuric status represents the most immediately actionable phenotype because it is clinically available and directly relevant to the discordant findings of the original trial. Stage of CKD, baseline inflammation, lipid-peroxidation burden, nutritional vitamin-E status, obesity, and use of modern cardiorenal drugs are additional candidate modifiers.

Broader Emerging Mechanisms Should Remain Hypothesis-Generating

The contemporary DKD literature includes several biologically interesting areas that may ultimately intersect with tocotrienols. Gut microbiota and microbial metabolites have been implicated in metabolic inflammation, intestinal permeability, and the generation of uremic toxins. Ferroptosis connects lipid peroxidation directly with regulated cell death. Epigenetic memory may perpetuate maladaptive renal responses despite improved glycemia [40,44,61].

These mechanisms are relevant because tocotrienols could theoretically affect lipid peroxidation, metabolic signaling, or inflammatory responses. However, the evidence is currently too indirect to support clinical claims. They should therefore be described as mechanistic research opportunities rather than as established renal actions of tocotrienols.

Safety and Drug–Supplement Interaction Considerations

The nutritional origin of tocotrienols should not lead to the assumption that clinical supplementation is automatically risk-free. Patients with DKD frequently receive multiple drugs, have altered renal physiology, and may have comorbid cardiovascular disease, hepatic disease, anemia, or nutritional abnormalities. Definitive trials should capture adverse events systematically rather than relying on passive reporting.

Safety assessments should include liver function, hematological parameters where relevant, bleeding-related events, glycemic variables, lipids, blood pressure, electrolyte disturbances, and adherence. Investigators should also record antiplatelet and anticoagulant treatment because vitamin E compounds have historically generated concern regarding hemostatic interactions at high exposure, even though the clinical relevance may vary by formulation and dose [20].

A data-safety monitoring framework would be appropriate for longer kidney studies, particularly once tocotrienols are combined with multiple contemporary cardiorenal medications. The objective should be to establish not merely efficacy but the net clinical value of adding another long-term treatment to an already complex medication regimen.

Clinical Interpretation at the Present Evidence Level

The available evidence does not support substituting palm tocotrienol-rich vitamin E for SGLT2 inhibitors, RAS blockade, finerenone, GLP-1 receptor agonists, or other indicated evidence-based treatments. The kidney-outcome evidence supporting established pharmacotherapy is quantitatively and qualitatively stronger than the current tocotrienol evidence.

The evidence also does not yet justify routine recommendation of tocotrienol supplementation specifically for renoprotection. A single modest-sized DKD trial demonstrating creatinine/eGFR improvement, particularly when UACR remained neutral and the signal disappeared after washout, cannot establish long-term prevention of kidney failure.

At the same time, dismissing the intervention completely would also be premature. Tocotrienols differ from many nutraceutical candidates because direct randomized human kidney evidence exists. That evidence is insufficient for clinical adoption but adequate to justify a better-designed confirmatory study. The most accurate present classification is therefore an investigational adjunct with preliminary direct human renal evidence and biologically plausible multi-pathway activity.

Broader Implications for Nutraceutical Research

The tocotrienol case illustrates a broader methodological problem in translational nutrition. Complex diseases invite multi-target interventions because their pathophysiology involves many interconnected pathways. Yet multi-target explanations can become scientifically unfalsifiable if every biological effect is interpreted as evidence of efficacy.

The MHR3 framework offers a more rigorous approach. Biological plausibility should identify specific residual pathways; pharmacokinetic measurements should establish that the intervention actually reaches the patient at relevant exposure; pharmacodynamic biomarkers should test whether the targeted pathway changes; and renal endpoints should establish whether those biological changes translate into kidney protection.

This sequence also provides a stopping rule. If adequate tocotrienol exposure fails to alter prespecified biological pathways and fails to improve chronic eGFR slope or other renal outcomes under optimized contemporary care, continued development as a renoprotective intervention would be difficult to justify. Conversely, reproducible renal benefit supported by exposure–response and biomarker coherence would justify progression to a larger outcome trial.

Limitations of the Present Review

This review is qualitative and therefore does not provide an exhaustive PRISMA-based search, formal risk-of-bias scoring across every included article, or pooled effect estimates. The approach was selected because the question requires integration of sparse tocotrienol renal trials with a large and rapidly evolving mechanistic and pharmacological literature.

Direct kidney-specific tocotrienol evidence remains limited. Consequently, several proposed pathways rely on broader human tocotrienol data or DKD pathophysiological evidence rather than direct demonstration that tocotrienols modify those pathways in patients with DKD. This distinction has been maintained throughout the review but remains an inherent translational limitation.

A further limitation is that DKD therapy is evolving rapidly. Combination regimens that were considered investigational only a few years ago are becoming increasingly relevant to clinical practice. The definition of residual renal risk will therefore continue to change as therapeutic uptake improves and additional combination-outcome data emerge.

Finally, biomarkers themselves have limitations. Serum creatinine, cystatin C, UACR, inflammatory markers, oxidative biomarkers, and tubular markers each interrogate only part of the disease process. Future research should therefore use triangulation across biological domains rather than relying on one surrogate endpoint.

Conclusion

Palm tocotrienol-rich vitamin E represents a scientifically credible but clinically unproven adjunctive hypothesis in DKD. Its relevance derives from a combination of multi-pathway biological plausibility and direct randomized human evidence suggesting improvement in creatinine-derived renal function. However, the neutral albuminuria response, limited sample size, incomplete mechanistic confirmation, formulation and bioavailability uncertainties, and disappearance of the filtration signal after treatment withdrawal prevent the current evidence from establishing disease-modifying renoprotection.

The modern treatment environment raises the evidentiary threshold considerably. RAS blockade, SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, and comprehensive cardiovascular-risk management provide a strong evidence-based foundation. Future tocotrienol research should therefore evaluate incremental benefit on top of this foundation rather than position tocotrienols as an alternative to it.

The proposed Multi-Hit Residual Renal Risk model identifies six interconnected domains—oxidative/redox dysregulation, inflammation, glycation/metabolic memory, endothelial/microvascular dysfunction, mitochondrial–metabolic–tubular stress, and regulated cell death/fibrosis—that may continue to drive progression despite contemporary treatment. Tocotrienols may plausibly influence several of these domains, but mechanistic overlap must be distinguished from clinically meaningful complementarity.

The decisive next step is an adequately powered, phenotype-aware randomized trial using a standardized palm tocotrienol formulation, pharmacokinetic confirmation, optimized contemporary background treatment, chronic eGFR slope, repeated UACR, cystatin C, tubular and mechanistic biomarkers, sufficient treatment duration, and planned post-treatment follow-up. Until such evidence becomes available, tocotrienol-rich vitamin E should be regarded neither as established renal therapy nor as an implausible intervention, but as a testable adjunctive strategy whose future should be determined by rigorous contemporary clinical investigation.

References

1. Ricciardi CA, Gnudi L (2021) Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies. *Metabolism* 124: 154890.
2. Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, et al. (2022) Molecular mechanisms and therapeutic targets for diabetic kidney disease. *Kidney Int* 102: 248-260.
3. Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, et al. (2023) Molecular pathways that drive diabetic kidney disease. *J Clin Invest* 133: e165654.
4. American Diabetes Association Professional Practice Committee for Diabetes (2026) 11. Chronic kidney disease and risk management: Standards of Care in Diabetes-2026. *Diabetes Care* 49: S246-S260.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. (2020) Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 383: 1436-1446.
6. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, et al. (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 383: 2219-2229.
7. Pitt B (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 385: 2252-2263.
8. EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. *N Engl J Med* 388: 117-127.
9. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, et al. (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 391: 109-121.
10. Yi TW, Sridhar VS, Scott J, Nardone M, Cherney D (2026) Next-generation therapeutics for diabetic kidney disease. *Nat Rev Nephrol* 22: 318-332.
11. Martinez Leon V, Hilburg R, Susztak K (2026) Mechanisms of diabetic kidney disease and established and emerging treatments. *Nat Rev Endocrinol* 22: 21-35.
12. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, et al. (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J* 43: 474-484.
13. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, et al. (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. *Diabetes Care* 45: 2991-2998.
14. Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, et al. (2025) Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. *N Engl J Med* 393: 533-543.
15. van Raalte DH, Bjornstad P, Cherney DZI, de Boer IH, Fioretto P, et al. (2024) Combination therapy for kidney disease in people with diabetes mellitus. *Nat Rev Nephrol* 20: 433-446.
16. Chaudhuri A, Ghanim H, Arora P (2022) Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials. *Diabetes Obes Metab* 24: 365-376.
17. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, et al. (2022) Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association and Kidney Disease: Improving Global Outcomes. *Diabetes Care* 45: 3075-3090.
18. KDIGO CKD Work Group (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int* 105: S117-S314.
19. Blum MF, Neuen BL, Grams ME (2025) Risk-directed

- management of chronic kidney disease. *Nat Rev Nephrol* 21: 287-298.
20. Ismail M, Alsalahi A, Imam MU, Ooi J, Khaza'ai H, et al. (2020) Safety and neuroprotective efficacy of palm oil and tocotrienol-rich fraction from palm oil: a systematic review. *Nutrients* 12: 521.
21. Zuo S, Wang G, Han Q, Xiao H, O Santos H, et al. (2020) The effects of tocotrienol supplementation on lipid profile: a meta-analysis of randomized controlled trials. *Complement Ther Med* 52: 102450.
22. Khor BH, Tiong HC, Tan SC, Wong SK, Chin KY, et al. (2021) Effects of tocotrienols supplementation on markers of inflammation and oxidative stress: a systematic review and meta-analysis of randomized controlled trials. *PLoS ONE* 16: e0255205.
23. Phang SCW, Ahmad B, Kadir KA, Palanisamy UD (2023) Effects of tocotrienol-rich fraction supplementation in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Adv Nutr* 14: 1159-1169.
24. Looi AD, Palanisamy UD, Moorthy M, Radhakrishnan AK (2025) Health benefits of palm tocotrienol-rich fraction: a systematic review of randomized controlled trials. *Nutr Rev* 83: 307-328.
25. Koay YY, Tan GCJ, Phang SCW, Ho JI, Chuar PF, et al. (2021) A Phase IIb randomized controlled trial investigating the effects of tocotrienol-rich vitamin E on diabetic kidney disease. *Nutrients* 13: 258.
26. Shi S, Ni L, Gao L, Wu X (2022) Comparison of nonalbuminuric and albuminuric diabetic kidney disease among patients with type 2 diabetes: a systematic review and meta-analysis. *Front Endocrinol* 13: 871272.
27. D'Marco L, Guerra-Torres X, Viejo I, Lopez-Romero L, Yugueros A, et al. (2022) Non-albuminuric diabetic kidney disease phenotype: beyond albuminuria. *touchREVIEWS Endocrinol* 18: 102-105.
28. Borg R, Persson F (2022) Non-albuminuric chronic kidney disease in diabetes: a different approach? *Indian J Med Res* 156: 685-686.
29. Jung CY, Yoo TH (2022) Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. *Diabetes Metab J* 46: 181-197.
30. DeFronzo RA, Reeves WB, Awad AS (2021) Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. *Nat Rev Nephrol* 17: 319-334.
31. Hesp AC, Schaub JA, Prasad PV, Vallon V, Laverman GD, et al. (2020) The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? *Kidney Int* 98: 579-589.
32. Wang Y (2023) Tubular injury in diabetic kidney disease: molecular mechanisms and potential therapeutic perspectives. *Front Endocrinol* 14: 1238927.
33. Tanase DM, Gosav EM, Anton MI, Floria M, Seritean Isac PN, et al. (2022) Oxidative stress and NRF2/KEAP1/ARE pathway in diabetic kidney disease: new perspectives. *Biomolecules* 12: 1227.
34. Kishi S, Nagasu H, Kidokoro K, Kashiwara N (2024) Oxidative stress and the role of redox signalling in chronic kidney disease. *Nat Rev Nephrol* 20: 101-119.
35. Rahayu I, Arfian N, Kustanti CY, Wahyuningsih MSH (2024) The effectiveness of antioxidant agents in delaying progression of diabetic nephropathy: a systematic review of randomized controlled trials. *BioImpacts* 15: 30129.
36. Thomas MC (2021) Targeting the pathobiology of diabetic kidney disease. *Adv Chronic Kidney Dis* 28: 282-289.
37. Yang M, Wang X, Han Y, Li C, Wei L, et al. (2021) Targeting the NLRP3 inflammasome in diabetic nephropathy. *Curr Med Chem* 28: 8810-8824.
38. Cao Z, Huang D, Tang C, Lu Y, Huang S, et al. (2022) Pyroptosis in diabetes and diabetic nephropathy. *Clin Chim Acta* 531: 188-196.
39. Fotheringham AK, Gallo LA, Borg DJ, Forbes JM (2022) Advanced glycation end products and chronic kidney disease: does the modern diet AGE the kidney? *Nutrients* 14: 2675.
40. Li X, Lu L, Hou W, Huang T, Chen X, et al. (2022) Epigenetics in the pathogenesis of diabetic nephropathy. *Acta Biochim Biophys Sin* 54: 163-172.
41. Yang J, Liu Z (2022) Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. *Front Endocrinol* 13: 816400.
42. Flemming NB, Pernoud L, Forbes JM, Gallo LA (2022) Mitochondrial dysfunction in individuals with diabetic kidney disease: a systematic review. *Cells* 11: 2481.
43. Wang H, Liu D, Zheng B, Yang Y, Qiao Y, et al. (2023) Emerging role of ferroptosis in diabetic kidney disease: molecular mechanisms and therapeutic opportunities. *Int J Biol Sci* 19: 2678-2694.
44. Mengstie MA, Seid MA, Gebeyehu NA, Adella GA, Kassie GA, et al. (2023) Ferroptosis in diabetic nephropathy: mechanisms and therapeutic implications. *Metab Open* 18: 100243.
45. Sanz AB, Sanchez-Niño MD, Ramos AM, Ortiz A (2023) Regulated cell death pathways in kidney disease. *Nat Rev Nephrol* 19: 281-299.
46. Miguel V, Shaw IW, Kramann R (2025) Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease. *Nat Rev Nephrol* 21: 39-56.
47. Chertow GM, Vart P, Jongs N, Toto RD, Gorris JL, et al. (2021) Effects of dapagliflozin in stage 4 chronic kidney disease. *J Am Soc Nephrol* 32: 2352-2361.
48. EMPA-KIDNEY Collaborative Group (2025) Long-term effects of empagliflozin in patients with chronic kidney disease. *N Engl J Med* 392: 777-787.
49. SMART-C Trialists' Consortium (2022) Impact of diabetes on the effects of sodium glucose cotransporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet* 400: 1788-1801.
50. Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, et al. (2022) Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. *J Am Soc Nephrol* 33: 225-237.
51. Chen JY (2025) Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials. *Am J Kidney Dis* 85: 555-569.e1.
52. Felix N, Gauza MM, Bittar V, Nogueira A, Costa TA, et al. (2025) Cardiovascular and kidney outcomes of glucagon-like peptide 1 receptor agonist therapy in type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. *Cardiorenal Med* 15: 98-107.
53. Provenzano M, Puchades MJ, Garofalo C, Jongs N, D'Marco L, et al. (2022) Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. *J Am Soc Nephrol* 33: 1569-1580.
54. Sharif M, Khan DA, Farhat K, Noor M, Khan MA, et al. (2023) Pharmacokinetics and bioavailability of tocotrienols in healthy human volunteers: a systematic review. *J Pak Med Assoc* 73: 603-610.

55. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, et al. (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. *N Engl J Med* 384: 129-139.
56. Sinha SK, Nicholas SB (2023) Pathomechanisms of diabetic kidney disease. *J Clin Med* 12: 7349.
57. Trugilho L, Alvarenga L, Cardozo L, Paiva B, Brito J, et al. (2025) Effects of tocotrienol on cardiovascular risk markers in patients with chronic kidney disease: a randomized controlled trial. *J Nutr Metab* 2025: 8482883.
58. Writing Group for the CKD Prognosis Consortium (2023) Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. *JAMA* 330: 1266-1277.
59. Das S, Devi Rajeswari V, Venkatraman G, Elumalai R, Dhanasekaran S, et al. (2024) Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: a systematic review. *Transl Res* 265: 71-87.
60. Tye SC, Denig P, Heerspink HJL (2021) Precision medicine approaches for diabetic kidney disease: opportunities and challenges. *Nephrol Dial Transplant* 36: ii3-ii9.
61. Wu X, Zhao L, Zhang Y, Li K, Yang J (2023) The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease. *Front Physiol* 14: 1166685.

Copyright: ©2026 Loso Judijanto. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.